It is interesting to study the effect of a single navitoclax treatment on different cancer types with high BCL-2, BCL-XL or BCL-W expressions, and to include navitoclax in a combination treatment with other chemotherapeutic agents that have moderate anti-tumor action as well as tumor regression. The gene discussed is BCL2L1; the disease is neoplasm.